FDA's Antiviral Drugs Advisory Committee
On July 20, will discuss data supporting supplemental NDAs for Burroughs Wellcome's Retrovir (zidovudine, AZT) for protection against maternal-fetal transmission of HIV. The committee will review data from SNDAs 19-655/023, 19-910/011 and 19-951/003 at Parklawn, conference rooms G, H, I & J. Open committee discussion begins at 8 a.m.; the open public hearing begins at 11 a.m. The ACTG 076 study of AZT for use in preventing maternal-fetal transmission of HIV found that when both mother and infant received AZT, the rate of transmission was reduced to 8.3% as compared to the placebo group transmission rate of 25.5% ("The Pink Sheet" Feb. 28, T&G-6)
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth